Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

Opinion
Video

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.